527PD - Pharmacogenetic predictors of severe chronic peripheral neuropathy in stage II-III colon cancer (CC) patients treated with oxaliplatin-based adjuvan...

Date 29 September 2012
Event ESMO Congress 2012
Session Gatrointestinal tumors, colorectal
Topics Colon and Rectal Cancer
Clinical Research
Basic Scientific Principles
Presenter Ana Custodio
Authors A. Custodio1, J. Moreno2, J. Aparicio3, J. Gallego Plazas4, C. Fernández Martos5, J. Maurel6, D. Ramos7, P. Cejas8, R. Madero9, J. Feliu8
  • 3Medical Oncology Department, La Fe University Hospital, 46009 - Valencia/ES
  • 4Medical Oncology Department, Elche University Hospital, 03202 - Elche/ES
  • 5Medical Oncology Department, Fundación Instituto Valenciano de Oncología, 4609 - Valencia/ES
  • 6Medical Oncology, Hospital Clinic i Provincial, 08036 - Barcelona/ES
  • 7Pathology Department, La Fe University Hospital, 46009 - Valencia/ES
  • 8Medical Oncology, LA PAZ UNIVERSITY HOSPITAL, 28046 - MADRID/ES
  • 9Biostatistics Unit, La Paz University Hospital, 28046 - Madrid/ES




Oxaliplatin-based CT is now the standard adjuvant therapy after resection of stage III and selected high-risk stage II CC. However, this treatment is often associated with cumulative peripheral neuropathy. Predicting individual patient risk for developing severe neuropathy could improve the quality of care by allowing the individualization of treatment. Our aim is to identify single nucleotide polymorphisms (SNPs) in genes involved in oxaliplatin sensitivity to predict severe (grade 2-3) oxaliplatin-induced chronic peripheral neuropathy (OXCPN) among stage II-III CC patients who received adjuvant CT.


DNA was extracted from formalin-fixed-paraffin-embedded samples from 202 surgically treated high-risk stage II (29.7%) and stage III (70.3%) CC patients receiving adjuvant oxaliplatin and fluoropyrimidines CT (25.24% FOLFOX, 74.75% CAPOX) from January 2004 to December 2008. Median follow-up was 51.4 months (7-96). Genotyping was performed for 35 SNPs in 18 genes involved in oxaliplatin metabolism (ERCC and XRCC groups), cell cycle and drug transport using MassARRAY (SEQUENOM) technology. A total of 177 stage II-III CC patients also treated with oxaliplatin-based CT were enrolled as a validation set.


Forty-eight (23.8%) patients experienced grade 2-3 OXCPN. The cyclin H (CCNH) (rs2230641) C/C genotype was associated with a higher risk of severe OXCPN (57.1% C/C, 24.2% C/T, 21.3% T/T; RR: 5.197, p = 0.041). In addition, patients harboring the CCNH (rs2230641) C/C and/or ATP-binding cassette subfamily G member (ABCG2) (rs3114018) A/A haplotype had a higher risk of grade 2-3 OXCPN compared to the CCNH (rs2230641) any T and ABCG2 (rs3114018) any C haplotype (36.5% vs. 19.6%, respectively; RR:2.36; 95% CI, 1.17-4.78; p = 0.022). The ability to predict severe OXCPN of this combined analysis was then independently validated in the second cohort (RR: 2.82; 95% CI, 1.41-5.63; p = 0.003).


Our data suggest that SNPs in CCNH and ABCG2 can predict the development of severe OXCPN in stage II-III CC patients. The analysis of these SNPs may be useful in personalized adjuvant CT.


All authors have declared no conflicts of interest.